The proteasomal and apoptotic phenotype determine bortezomib sensitivity of non-small cell lung cancer cells

Bortezomib is a novel anti-cancer agent which has shown promising activity in non-small lung cancer (NSCLC) patients. However, only a subset of patients respond to this treatment. We show that NSCLC cell lines are differentially sensitive to bortezomib, IC(50 )values ranging from 5 to 83 nM. The apo...

Descripción completa

Detalles Bibliográficos
Autores principales: Voortman, Jens, Chęcińska, Agnieszka, Giaccone, Giuseppe
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194734/
https://www.ncbi.nlm.nih.gov/pubmed/18021420
http://dx.doi.org/10.1186/1476-4598-6-73

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194734/
https://www.ncbi.nlm.nih.gov/pubmed/18021420
http://dx.doi.org/10.1186/1476-4598-6-73

Ejemplares similares